Palifermin
- Generic Name
- Palifermin
- Brand Names
- Kepivance
- Drug Type
- Biotech
- CAS Number
- 162394-19-6
- Unique Ingredient Identifier
- QMS40680K6
- Background
Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli.
Palifermin was granted FDA approval on 15 December 2004.
- Indication
For treatment of oral mucositis associated with chemotherapy and radiation therapy.
- Associated Conditions
- Oral Mucositis
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
- Conditions
- Myeloma
- Interventions
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02114502
Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
- Conditions
- Toxic Epidermal NecrolysisStevens-Johnson Syndrome
- Interventions
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Brett King
- Target Recruit Count
- 1
- Registration Number
- NCT02037347
- Locations
- 🇺🇸
Bridgeport Hospital, Bridgeport, Connecticut, United States
🇺🇸Yale-New Haven Hospital, New Haven, Connecticut, United States
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
- Conditions
- Multiple MyelomaNon-Hodgkin's LymphomaLeukemiaMyelodysplastic Syndrome
- Interventions
- Procedure: peripheral blood stem cell transplantationRadiation: Total-Body Irradiation (TBI)
- First Posted Date
- 2012-12-11
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 82
- Registration Number
- NCT01746849
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
- Conditions
- T-cell Non-Hodgkin Lymphoma
- Interventions
- Procedure: Stem Cell CollectionProcedure: Stem Cell Transplant
- First Posted Date
- 2012-12-10
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT01746173
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2019-04-30
- Target Recruit Count
- 40
- Registration Number
- NCT01712945
- Locations
- 🇬🇧
Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2011-08-22
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 78
- Registration Number
- NCT01421173
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- Conditions
- X-linked Severe Combined Immunodeficiency (XSCID)
- Interventions
- Biological: Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector
- First Posted Date
- 2011-03-01
- Last Posted Date
- 2025-05-20
- Target Recruit Count
- 40
- Registration Number
- NCT01306019
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
- Conditions
- Myeloma
- Interventions
- Procedure: Stem Cell Transplant
- First Posted Date
- 2010-11-10
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT01237951
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 81
- Registration Number
- NCT01200329
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study to Characterize the Effect of Heparin on Palifermin Activity
- First Posted Date
- 2010-07-15
- Last Posted Date
- 2014-11-06
- Lead Sponsor
- Swedish Orphan Biovitrum
- Target Recruit Count
- 44
- Registration Number
- NCT01163097
- Locations
- 🇺🇸
New Orleans Center for Clinical Research (NOCCR), Knoxville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.